25(22):3357- 61, 2007. 40. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk -Shina T, Brown PD, Chakravarti A, Curran WJ, Jr., Mehta MP. Dose- dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 31(32):4085- 91, 2013. PMCID: PMC3816958. 41. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol. 10(1):98- 103, 2008. PMCID: PMC2600844. Pro00054746: RESIST Study Version: 20171011 PT-PhI-II v05.22.12 Duke Cancer Institute Page 51 CONFIDENTIAL 42. Slingluff CL, Jr., Speiser DE. Progress and controversies in developing cancer vaccines. J Transl Med. 3(1):18, 2005. PMCID: PMC1142519. 43. Pilla L, Rivoltini L, Patuzzo R, Marra ri A, Valdagni R, Parmiani G. Multipeptide vaccination in cancer patients. Expert Opin Biol Ther. 9(8):1043- 55, 2009. 44.